CN106458942A - 微管溶素衍生物 - Google Patents

微管溶素衍生物 Download PDF

Info

Publication number: CN106458942A
Authority: CN; China
Prior art keywords: cancer; compound; antibody; mmol; methyl
Prior art date: 2014-04-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201580031041.XA

Other languages

English (en)

Chinese (zh)

Inventor

L·金吉帕里

D·托阿德尔

F·王

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MedImmune Ltd

Original Assignee

MedImmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-11

Filing date

2015-04-10

Publication date

2017-02-22

2015-04-10 Application filed by MedImmune Ltd filed Critical MedImmune Ltd

2017-02-22 Publication of CN106458942A publication Critical patent/CN106458942A/zh

Status Pending legal-status Critical Current

Links

0 CC*C*(C*(C(C=C1)=O)C1=O)=* Chemical compound CC*C*(C*(C(C=C1)=O)C1=O)=* 0.000 description 7
BWXHZEWWQASVOP-UHFFFAOYSA-N CC(C(CC1OC(C)=O)N(C)C(OC(C)(C)C)=O)S2C1=NC(CO[Si](C)(C)C(C)(C)C)=C2 Chemical compound CC(C(CC1OC(C)=O)N(C)C(OC(C)(C)C)=O)S2C1=NC(CO[Si](C)(C)C(C)(C)C)=C2 BWXHZEWWQASVOP-UHFFFAOYSA-N 0.000 description 1
LOALDJQLEHJKNX-ZDUSSCGKSA-N CC(C)(C)OC(N[C@@H](CC1=CC=CCC=C1)C=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CC1=CC=CCC=C1)C=O)=O LOALDJQLEHJKNX-ZDUSSCGKSA-N 0.000 description 1
IUXROKATSPNFQU-CQSZACIVSA-N CC(C)(C)OC(N[C@H](CC(C(OC)=O)=C)Cc(cc1)ccc1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N[C@H](CC(C(OC)=O)=C)Cc(cc1)ccc1[N+]([O-])=O)=O IUXROKATSPNFQU-CQSZACIVSA-N 0.000 description 1
WJZXFGPVQFIRSY-DNOWBOINSA-N CC(C1)(C[C@H]2C(OC)=O)C1C1=C2C=CCCC1 Chemical compound CC(C1)(C[C@H]2C(OC)=O)C1C1=C2C=CCCC1 WJZXFGPVQFIRSY-DNOWBOINSA-N 0.000 description 1
WLSRPNZNBXZQET-GXTWGEPZSA-N C[C@@H](C[C@H](Cc1ccccc1)N1C(OC(C)(C)C)=O)C1=O Chemical compound C[C@@H](C[C@H](Cc1ccccc1)N1C(OC(C)(C)C)=O)C1=O WLSRPNZNBXZQET-GXTWGEPZSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Crystallography & Structural Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

CN201580031041.XA 2014-04-11 2015-04-10 微管溶素衍生物 Pending CN106458942A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461978460P	2014-04-11	2014-04-11
US61/978,460		2014-04-11
PCT/US2015/025235 WO2015157594A1 (en)	2014-04-11	2015-04-10	Tubulysin derivatives

Publications (1)

Publication Number	Publication Date
CN106458942A true CN106458942A (zh)	2017-02-22

Family

ID=54264545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580031041.XA Pending CN106458942A (zh)	2014-04-11	2015-04-10	微管溶素衍生物

Country Status (19)

Country	Link
US (2)	US9427479B2 (2)
EP (1)	EP3129362A4 (2)
JP (1)	JP2017510661A (2)
KR (1)	KR20160142392A (2)
CN (1)	CN106458942A (2)
AR (1)	AR100006A1 (2)
AU (1)	AU2015243379B2 (2)
CA (1)	CA2945318A1 (2)
CL (1)	CL2016002548A1 (2)
EA (1)	EA032203B1 (2)
IL (1)	IL247822A0 (2)
MA (1)	MA39862A (2)
MX (1)	MX2016013373A (2)
NZ (1)	NZ725131A (2)
PH (1)	PH12016501995A1 (2)
SG (1)	SG11201608203RA (2)
TW (1)	TW201625662A (2)
UY (1)	UY36075A (2)
WO (1)	WO2015157594A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109456212A (zh) *	2018-12-03	2019-03-12	康化（上海）新药研发有限公司	一种沙库比曲中间体的合成方法
CN115867563A (zh) *	2020-06-24	2023-03-28	里珍纳龙药品有限公司	微管溶素及蛋白质-微管溶素偶联物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201608192SA (en)	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
EA032203B1 (ru) *	2014-04-11	2019-04-30	МЕДИММЬЮН ЭлЭлСи	Производные тубулизина
US10808007B2 (en)	2015-02-25	2020-10-20	William Marsh Rice University	Desacetoxytubulysin H and analogs thereof
MY192146A (en)	2015-11-10	2022-08-01	Medimmune Llc	Binding molecules specific for asct2 and uses thereof
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
KR20180090290A (ko)	2015-12-04	2018-08-10	시애틀 지네틱스, 인크.	사차화 튜불리신 화합물들의 컨쥬게이트들
EP3411371A1 (en) *	2016-02-01	2018-12-12	Pfizer Inc	Tubulysin analogs and methods for their preparation
GEP20227398B (en)	2016-04-15	2022-07-25	Macrogenics Inc	Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
EP3525829A1 (en)	2016-10-11	2019-08-21	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
MA51447A (fr)	2017-08-01	2020-06-10	Medimmune Llc	Conjugué anticorps monoclonal-médicament dirigé contre bcma
EP3621652A4 (en)	2017-12-31	2021-01-13	Hangzhou DAC Biotech Co, Ltd	CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS
JP7590328B2 (ja)	2018-12-21	2024-11-26	レゲネロンファーマシューティカルス，インコーポレーテッド	ツブリシン及びタンパク質－ツブリシンコンジュゲート
TWI753252B (zh) *	2019-05-03	2022-01-21	中國大陸商杭州多禧生物科技有限公司	含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物
PH12021500050A1 (en) *	2019-06-24	2022-05-02	Hangzhou Dac Biotech Co Ltd	A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
BR112023004415A2 (pt)	2020-09-11	2023-05-09	Medimmune Ltd	Moléculas terapêuticas de ligação a b7-h4
US12065496B2 (en)	2021-11-10	2024-08-20	Astrazeneca Ab	Antibody molecules and conjugates
GB202117928D0 (en)	2021-12-11	2022-01-26	Cancer Research Tech Ltd	Immunotherapy for cancer
CA3259492A1 (en)	2022-06-27	2024-01-04	Astrazeneca Ab	COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2025078841A2 (en)	2023-10-11	2025-04-17	Antikor Biopharma Limited	Antibodies, conjugates, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102725001A (zh) *	2009-08-03	2012-10-10	米德列斯公司	抗增殖化合物、其缀合物、其方法及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7064211B2 (en) *	2002-03-22	2006-06-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof
JP2008522624A (ja) *	2004-12-09	2008-07-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
IT1394860B1 (it) *	2009-07-22	2012-07-20	Kemotech S R L	Composti farmaceutici
CN104185477B (zh) *	2011-11-17	2017-05-24	辉瑞公司	细胞毒性肽及其抗体‑药物缀合物
RU2014124984A (ru) *	2011-12-05	2016-01-27	Идженика Биотерапьютикс, Инк.	Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
LT2956173T (lt) *	2013-02-14	2017-06-26	Bristol-Myers Squibb Company	Tubulizino junginiai, gavimo ir panaudojimo būdai
WO2015155345A1 (en)	2014-04-11	2015-10-15	Medimmune Limited	Antibodies and antibody-drug conjugates
SG11201608192SA (en) *	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
EA032203B1 (ru) *	2014-04-11	2019-04-30	МЕДИММЬЮН ЭлЭлСи	Производные тубулизина

2015
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102725001A (zh) *	2009-08-03	2012-10-10	米德列斯公司	抗增殖化合物、其缀合物、其方法及其用途
US20130197259A1 (en) *	2009-08-03	2013-08-01	Medarex, Inc.	Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109456212A (zh) *	2018-12-03	2019-03-12	康化（上海）新药研发有限公司	一种沙库比曲中间体的合成方法
CN115867563A (zh) *	2020-06-24	2023-03-28	里珍纳龙药品有限公司	微管溶素及蛋白质-微管溶素偶联物
CN115867563B (zh) *	2020-06-24	2025-06-27	里珍纳龙药品有限公司	微管溶素及蛋白质-微管溶素偶联物

Also Published As

Publication number	Publication date
KR20160142392A (ko)	2016-12-12
EA201691963A1 (ru)	2017-06-30
CA2945318A1 (en)	2015-10-15
SG11201608203RA (en)	2016-10-28
UY36075A (es)	2015-10-30
TW201625662A (zh)	2016-07-16
US10159745B2 (en)	2018-12-25
MA39862A (fr)	2017-02-15
IL247822A0 (en)	2016-11-30
AU2015243379A1 (en)	2016-11-03
AR100006A1 (es)	2016-08-31
US20160339114A1 (en)	2016-11-24
PH12016501995A1 (en)	2017-01-09
EP3129362A4 (en)	2017-08-23
EA032203B1 (ru)	2019-04-30
US20150291657A1 (en)	2015-10-15
MX2016013373A (es)	2017-05-02
EP3129362A1 (en)	2017-02-15
CL2016002548A1 (es)	2017-02-24
US9427479B2 (en)	2016-08-30
JP2017510661A (ja)	2017-04-13
AU2015243379B2 (en)	2018-02-01
WO2015157594A1 (en)	2015-10-15
NZ725131A (en)	2018-03-23

Legal Events

Date	Code	Title	Description
2017-02-22	C06	Publication
2017-02-22	PB01	Publication
2017-05-10	SE01	Entry into force of request for substantive examination
2017-05-10	SE01	Entry into force of request for substantive examination
2019-07-30	WD01	Invention patent application deemed withdrawn after publication
2019-07-30	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20170222

Publication	Publication Date	Title
CN106458942A (zh)	2017-02-22	微管溶素衍生物
JP7663514B2 (ja)	2025-04-16	Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
EP3468996B1 (en)	2022-05-04	Anti-egfr antibody drug conjugates
JP6560681B2 (ja)	2019-08-14	薬物結合体のためのスルホンアミド含有連結系
JP6892826B2 (ja)	2021-06-23	Ｃｄ４８抗体及びその複合体
JP2023530128A (ja)	2023-07-13	細胞結合分子とカンプトテシン類縁体との共役体
US20230241242A1 (en)	2023-08-03	Preparation method for antibody medicament conjugate
KR20190015755A (ko)	2019-02-14	항-b7-h3 항체 및 항체 약물 콘쥬게이트
EP4480499A1 (en)	2024-12-25	Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
KR20210106467A (ko)	2021-08-30	튜불리신 및 단백질-튜불리신 접합체
US20240042051A1 (en)	2024-02-08	Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4623937A1 (en)	2025-10-01	Anti-tumor compound and use thereof
WO2021222783A1 (en)	2021-11-04	Anti-tm4sf1 antibody drug conjugates and methods of using same
CN121219013A (zh)	2025-12-26	多弹头抗体偶联药物及其制备方法和用途
EP4696331A1 (en)	2026-02-18	Anti-cdh6 antibody-drug conjugate and use thereof
JP2026514033A (ja)	2026-05-01	抗ｃｄｈ６抗体－薬物コンジュゲート及びその使用
EP4536290A1 (en)	2025-04-16	Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
NZ788873A (en)	2022-07-01	Anti-B7-H3 antibodies and antibody drug conjugates